Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
While Semaglutide GLP-1 is generally considered safe and effective for most individuals with obesity, there are certain groups of people who may not be able to use Semaglutide GLP-1 due to potential risks and contraindications
GLP-1 helps reduce this inflammatory burden, which is why people with autoimmune diseases often feel better when they lose even 510% of body weight
First, sugar cravings often have psychological and behavioral components that extend beyond physiological hunger
Sakr said he is hearing from patients interested in the generic semaglutide injections, adding: "I'm expecting there will be super high demand for them" [Source: cbc.ca/news/canada/calgary/generic-ozempic-alberta-9.7211507]
